Introduction {#section1-2192568219841046}
============

Randomized controlled trials (RCTs) are pivotal in establishing the safety and efficacy of novel spinal devices. Spinal device trials are designed either as noninferiority (NI) or superiority trials. In NI trials, the aim is to demonstrate that an investigational device is similar to an accepted surgical procedure or device by showing that the investigational device is not worse (by a small margin). In superiority trials, the goal is to show that the investigational device is superior to a control treatment, which may be nonsurgical care or a gold standard surgical procedure.^[@bibr1-2192568219841046]^

In the United States, most investigational device exemption (IDE) studies of novel spinal devices are designed as NI trials because of effect size, secondary benefits, and ethical considerations.^[@bibr2-2192568219841046],[@bibr3-2192568219841046]^ Many of these NI trials also test for superiority of the investigational device (NI + S), since sponsors are under pressure from physicians and payers to show improvements in safety, efficacy, and cost-effectiveness. The nuances associated with post hoc tests of superiority in this setting can make interpretation of such superiority claims challenging and potentially misleading.^[@bibr4-2192568219841046]^ The aims of NI versus superiority trials differ substantially, so the methodology associated with design, analysis, and interpretation is also different. For example, it is conservative to analyze the intention-to-treat (ITT) population for superiority analyses, but it is not conservative for NI analyses since any confounding events will drive the result toward equivalence.^[@bibr1-2192568219841046],[@bibr5-2192568219841046][@bibr6-2192568219841046]-[@bibr7-2192568219841046]^ Additionally, post hoc specification of hypotheses must be avoided in confirmatory trials,^[@bibr4-2192568219841046]^ which requires that superiority analyses are well-defined in the statistical plan a priori. Finally, it is critical to address not only the statistical superiority but also the clinical significance of the differences observed. This is particularly true when a NI margin is imposed for the primary analysis, so that interpretation can be symmetric with less potential for bias.^[@bibr8-2192568219841046]^

The purpose of this study was to review the literature for reports of randomized controlled trials of spinal devices from the year 2000 to present. For each report, the primary study design was classified as NI, superiority, or NI with an additional predefined superiority analysis (NI + S). For each trial, superiority claims were identified and were assessed for potential sources of bias by multiple reviewers using a standardized tool. The hypothesis was that NI trials would predominate, and that superiority claims derived from NI trials would have a greater risk of potential bias and less reliability.

Methods {#section2-2192568219841046}
=======

Study Selection {#section3-2192568219841046}
---------------

This systematic review was performed according to the guidelines provided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.^[@bibr9-2192568219841046]^ Search criteria were developed to identify RCTs of medical devices or biologics for the spine through PubMed/MEDLINE, Embase, [ClinicalTrials.gov](https://ClinicalTrials.gov), the World Health Organization's International Clinical Trials Registry Platform (ICTRP), as well as the Food and Drug Administration's (FDA) databases on premarket approvals (PMA), postapproval studies (PAS), and proceedings from FDA advisory committee meetings of the Orthopaedic and Rehabilitation Devices Panel. Search filters included information available in the English language and publication since the year 2000 to focus on more recent trends in trial design, analysis, and interpretation. Search terms and inclusion/exclusion criteria for record screening are summarized in [Table 1](#table1-2192568219841046){ref-type="table"} for the PubMed and Embase searches while further details for these and the other databases are provided in Appendix A (see Supplementary Material available in the online version of the article). Two independent researchers screened the identified records for inclusion and exclusion. The final search of each database was completed between May 15 and June 15, 2018. When relevant studies were identified through one database, the other databases were further queried to identify protocols or reports that may provide supplemental study information for data extraction. Only the primary endpoint and primary outcomes were evaluated in this review, considering those were the basis for trial design.

###### 

Search Terms and Screening Criteria Used for the PubMed and Embase Databases.

![](10.1177_2192568219841046-table1)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Anatomical Terms                                                                                                                                                                                  Inclusion Criteria
  1\. Spine2. Lumbar3. Lumbosacral4. Thoracolumbar5. Cervical6. Intervertebral disc                                                                                                                 Spinal devices or biologicsRandomized controlled trials (RCTs) with description of trial design (noninferiority or superiority)Reports on the primary study endpoint
  Device Terms                                                                                                                                                                                      Exclusion Criteria
  7\. Device8. Instrumentation9. Spacer10. Cage11. Interbody fusion12. Annular (anular) closure13. Fixation14. Stimulator15. Prosthesis16. Replacement17. Arthroplasty18. Biomaterial19. Biologic   Drugs, diagnostics, or nonsurgical management methodsSurgical techniques or other non--device-based interventions (navigation and robot-assisted surgery were inclusive)Nonclinical studies (eg, preclinical research or economics analyses)Non-RCT studies (eg, single-arm or nonrandomized studies)Insufficient description of study design (eg, noninferiority or superiority)Information from multiple publications about a single clinical study were merged, but only for the primary endpoint
  Study Design Terms                                                                                                                                                                                Search Filters
  20\. Investigational device exemption (IDE)21. Non-inferior(-ity)22. Noninferior(-ity)23. Superiority24. Randomized controlled trial (RCT)25. Meta-analysis26. Review                             Language: EnglishYears: 2000 to PresentStudy type: Randomized Controlled Trial
  Search Term Combination Strategy                                                                                                                                                                  
  \[1-6\]/or AND {(\[7-19\]/or AND \[24\]) or \[20-24\]/or} NOT \[25-26\]/or                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data Extraction {#section4-2192568219841046}
---------------

Relevant data was extracted from each included study by 2 independent researchers. Discrepancies in identifying the study design were resolved through discussion and identification of additional, clarifying documentation in five cases. The data of interest for this review included the study objective, hypotheses for primary endpoints (NI or superiority), margins or effect size used in trial design, primary outcomes and endpoints, sample sizes, conclusions or claims made in the report (NI or superiority), treatment effects of superior devices, and any statistical or clinical significance considerations relating to the superiority claims. When multiple articles reported on the same study (eg, outcomes at different time points), each article was screened for the data of interest related to the a priori study design and primary endpoint.

Risk of Bias Assessment {#section5-2192568219841046}
-----------------------

The general risk of bias was evaluated for each study using the Cochrane Risk of Bias Tool for Randomized Controlled Trials^[@bibr10-2192568219841046]^ and interpreted according to the key domains described by Pavon et al^[@bibr11-2192568219841046]^ (Supplementary Table S1, Appendix B). The reporting of any financial disclosures, or lack thereof, was also noted but was not considered in the overall risk of bias evaluation. Additionally, the risk of bias specifically related to superiority claims was assessed. The criteria for this assessment included analyses that were not specified a priori, analysis of the ITT population, post hoc modification of primary outcomes, and any sensitivity analyses performed on the analysis population or missing value imputation (Supplementary Table S2, Appendix B). The reporting of confidence intervals for superiority claims was also noted but was not considered in the overall risk of bias for the superiority claim.

Results {#section6-2192568219841046}
=======

Overview of Included Studies {#section7-2192568219841046}
----------------------------

Across all 7 databases, 1895 unique records were identified, and 41 unique studies met the inclusion/exclusion criteria ([Figure 1](#fig1-2192568219841046){ref-type="fig"}). Among these 41 studies, the most common investigational spinal devices were cervical disc replacements (9/41; 22%), followed by interspinous/interlaminar spacers (7/41; 17%), biologics used to support spinal fusion (7/41; 17%), lumbar disc replacements (6/41; 15%), vertebroplasty materials (2/41; 5%), spinal cord stimulators (2/41; 5%), interbody fusion cages (2/41; 5%), and 1 each (2%) of a dural sealant, an adhesion barrier gel, an annular closure device, a sacroiliac joint fusion device, a dynamic posterolateral pedicle screw system, and a surgical robot used for pedicle screw placement ([Table 2](#table2-2192568219841046){ref-type="table"}).

![PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) diagram demonstrating flow of records from identification through inclusion.](10.1177_2192568219841046-fig1){#fig1-2192568219841046}

###### 

Summary of Included Studies.

![](10.1177_2192568219841046-table2)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Device Type                   Device           Study Identifier                                                                      Citation                                                                                              Study Comparators                                       Sample Size    Risk of Study Bias
  ----------------------------- ---------------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ------------------------------------------------------- -------------- --------------------
  Cervical disc replacement     BRYAN            NCT00437190\                                                                          Heller et al, 2009^[@bibr33-2192568219841046]^                                                        BRYAN vs ACDF at 2 years                                Test: 242\     L
                                                 PMA P060023                                                                                                                                                                                                                                         Control: 221   

  Prestige ST                   NCT00642876\     Mummaneni et al, 2007^[@bibr15-2192568219841046]^                                     Prestige ST vs ACDF at 2 years                                                                        Test: 276\                                              M              
                                PMA P060018                                                                                                                                                                                                  Control: 265                                                           

  Prestige LP                   NCT00637156\     Gornet et al, 2017^[@bibr37-2192568219841046]^                                        2-level Prestige vs ACDF at 2 years                                                                   Test: 209\                                              L              
                                PMA P090029                                                                                                                                                                                                  Control: 188                                                           

  ProDisc-C                     NCT00291018\     Murrey et al, 2009^[@bibr40-2192568219841046]^                                        ProDisc-C vs ACDF at 2 years                                                                          Test: 103\                                              M              
                                PMA P070001                                                                                                                                                                                                  Control: 106                                                           

  Kineflex\|C                   NCT00374413      Coric et al, 2011^[@bibr42-2192568219841046]^                                         Kineflex\|C vs ACDF at 2 years                                                                        Test: 136\                                              M              
                                                                                                                                                                                                                                             Control: 133                                                           

  Mobi-C                        NCT00389597\     Hisey et al, 2014^[@bibr51-2192568219841046]^                                         1-level Mobi-C vs ACDF at 2 years                                                                     Test: 164\                                              L              
                                PMA P110002\                                                                                                                                                                                                 Control: 81                                                            
                                PMA P110009                                                                                                                                                                                                                                                                         

                                                 Davis et al, 2013^[@bibr35-2192568219841046]^                                         2-level Mobi-C vs ACDF at 2 years                                                                     Test: 225\                                              L              
                                                                                                                                                                                                                                             Control: 105                                                           

  Secure-C                      NCT00882661\     Vaccaro et al, 2013^[@bibr16-2192568219841046]^                                       SECURE-C vs ACDF at 2 years                                                                           Test: 240\                                              M              
                                PMA P100003                                                                                                                                                                                                  Control: 140                                                           

  PCM Cervical Disc             NCT00578812\     Phillips et al, 2013^[@bibr41-2192568219841046]^                                      PCM vs ACDF\                                                                                          Test: 189\                                              M              
                                PMA P100012                                                                                            at 2 years                                                                                            Control: 153                                                           

  Lumbar disc replacement       Charite          NCT00215306\                                                                          Blumenthal et al, 2005^[@bibr52-2192568219841046]^                                                    Charite vs ALIF\                                        Test: 205\     M
                                                 PMA P040006                                                                                                                                                                                 at 2 years                                              Control: 99    

  ProDisc-L                     IDE \#G010133\   Zigler et al, 2007^[@bibr43-2192568219841046]^                                        1-level ProDisc-L vs fusion at 2 years                                                                Test: 161\                                              L              
                                PMA P050010                                                                                                                                                                                                  Control: 75                                                            

                                NCT00295009      Delamarter et al, 2011^[@bibr53-2192568219841046]^                                    2-level ProDisc-L vs fusion at 2 years                                                                Test: 165\                                              M              
                                                                                                                                                                                                                                             Control: 72                                                            

  MAVERICK                      NCT00635843      Gornet et al, 2011^[@bibr17-2192568219841046]^                                        MAVERICK vs ALIF at 2 years                                                                           Test: 405\                                              L              
                                                                                                                                                                                                                                             Control: 172                                                           

  Kineflex                      NCT00292292      Pettine et al, 2011^[@bibr26-2192568219841046]^                                       Kineflex vs Charite at 2 years                                                                        Test: 33\                                               M              
                                                                                                                                                                                                                                             Control: 31                                                            

  activL                        NCT00589797\     Garcia et al, 2015^[@bibr18-2192568219841046]^                                        activL vs ProDisc-L or Charite at 2 years                                                             Test: 218\                                              L              
                                PMA P120024                                                                                                                                                                                                  Control: 106                                                           

  Biologic: Fusion              OP-1 Putty       NCT00677950                                                                           Vaccaro et al, 2008^[@bibr54-2192568219841046]^                                                       OP-1 vs autograft (noninstrumented fusion) at 2 years   Test: 208\     L
                                                                                                                                                                                                                                                                                                     Control: 87    

                                ISRCTN43648350   Delawi et al, 2016^[@bibr55-2192568219841046]^                                        OP-1 vs autograft (instrumented fusion) at 1 year                                                     Test: 60\                                               L              
                                                                                                                                                                                                                                             Control: 59                                                            

  Novosis (rhBMP-2)             NCT01764906      Cho et al, 2017^[@bibr56-2192568219841046]^                                           Novosis vs autograft at 6 months                                                                      Test: 42\                                               L              
                                                                                                                                                                                                                                             Control: 51                                                            

  Bonion                        NCT01615328      Yi et al, 2015^[@bibr57-2192568219841046]^                                            Bonion vs. βTCP/HA allografts at 2 years                                                              Test: 38\                                               M              
                                                                                                                                                                                                                                             Control: 39                                                            

  i-Factor                      NCT00310440\     Arnold et al, 2016^[@bibr58-2192568219841046]^                                        i-Factor vs autograft at 1 year                                                                       Test: 165\                                              M              
                                PMA P140019                                                                                                                                                                                                  Control: 154                                                           

  INFUSE with LT-cage           PMA P000058      Burkus et al, 2002^[@bibr59-2192568219841046]^ and 2003^[@bibr60-2192568219841046]^   INFUSE vs autograft at 2 years                                                                        Test: 143\                                              L              
                                                                                                                                                                                                                                             Control: 136                                                           

  AMPLIFY (rhBMP-2)             PMA P050036      FDA Executive Summary^[@bibr61-2192568219841046]^                                     AMPLIFY vs autograft at 2 years                                                                       Test: 239\                                              L              
                                                                                                                                                                                                                                             Control: 224                                                           

  Adhesion barrier              Oxiplex/SP       PMA P070023                                                                           Rhyne et al, 2012^[@bibr62-2192568219841046]^ and FDA Executive Summary^[@bibr24-2192568219841046]^   Surgery + Oxiplex vs surgery alone at 6 months          Test: 177\     L
                                                                                                                                                                                                                                                                                                     Control: 175   

  Vertebroplasty                Cortoss          NCT00290862                                                                           Bae et al, 2012^[@bibr63-2192568219841046]^                                                           Cortoss vs PMMA at 2 years                              Test: 162\     L
                                                                                                                                                                                                                                                                                                     Control: 94    

                                Kiva             NCT01123512                                                                           Tutton et al, 2015^[@bibr64-2192568219841046]^                                                        Kiva vs. balloon kyphoplasty at 1 year                  Test: 147\     L
                                                                                                                                                                                                                                                                                                     Control: 153   

  Dural Sealant                 Adherus          NCT01158378\                                                                          Strong et al, 2017^[@bibr27-2192568219841046]^                                                        Adherus vs DuraSeal at 4 months                         Test: 124\     L
                                                 PMA P130014                                                                                                                                                                                                                                         Control: 126   

  Interlaminar/Spinous device   Superion         NCT00692276\                                                                          Patel et al, 2015^[@bibr28-2192568219841046]^                                                         Superion vs X-Stop at 2 years                           Test: 190\     M
                                                 PMA P140004                                                                                                                                                                                                                                         Control: 201   

  Coflex                        NCT00534235\     Davis et al, 2013^[@bibr46-2192568219841046]^                                         Coflex vs fusion at 1-2 levels at 2 years                                                             Test: 230\                                              L              
                                PMA P110008                                                                                                                                                                                                  Control: 114                                                           

                                NCT01316211      Schmidt et al, 2018^[@bibr25-2192568219841046]^                                       Coflex vs decompressive surgery at 2 years                                                            Test: 115\                                              L              
                                                                                                                                                                                                                                             Control: 115                                                           

  Aperius                       NCT00905359      Meyer et al, 2018^[@bibr47-2192568219841046]^                                         Aperius vs decompressive surgery at 2 years                                                           Test: 82\                                               M              
                                                                                                                                                                                                                                             Control: 81                                                            

  X-Stop                        N/A              Strömqvist et al, 2013^[@bibr48-2192568219841046]^                                    X-Stop vs decompressive surgery at 2 years                                                            Test: 50\                                               M              
                                                                                                                                                                                                                                             Control: 50                                                            

                                PMA P040001      FDA SSED^[@bibr44-2192568219841046]^ and memo^[@bibr23-2192568219841046]^             X-Stop vs nonsurgical management at 2 years                                                           Test: 100\                                              M              
                                                                                                                                                                                                                                             Control: 91                                                            

  DIAM                          IDE G050025\     FDA Executive Summary^[@bibr21-2192568219841046]^                                     DIAM vs nonsurgical management at 1 year                                                              Test: 181\                                              H              
                                PMA P140007                                                                                                                                                                                                  Control: 100                                                           

  Annular closure device        Barricaid        NCT01283438                                                                           Thome et al, 2018^[@bibr19-2192568219841046]^                                                         Barricaid vs discectomy only at 2 years                 Test: 276\     L
                                                                                                                                                                                                                                                                                                     Control: 278   

  Sacroiliac joint fusion       iFuse            NCT01640353                                                                           Whang et al, 2015^[@bibr20-2192568219841046]^                                                         iFuse vs nonsurgical management at 6 months             Test: 102\     M
                                                                                                                                                                                                                                                                                                     Control: 46    

  Interbody fusion cage         Novomax          N/A                                                                                   Lee et al, 2016^[@bibr29-2192568219841046]^                                                           NovoMax vs titanium cage at 1 year                      Test: 41\      L
                                                                                                                                                                                                                                                                                                     Control: 39    

                                BAK/C            PMA P980048                                                                           Hacker et al, 2000^[@bibr65-2192568219841046]^ and FDA SSED^[@bibr66-2192568219841046]^               BAK/C vs bone grafting at 2 years                       Test: 164\     M
                                                                                                                                                                                                                                                                                                     Control: 134   

  Dynamic stabilization         Dynesys          NCT00759057\                                                                          FDA Executive Summary^[@bibr67-2192568219841046]^                                                     Dynesys vs posterolateral fusion at 2 years             Test: 253\     M
                                                 PMA P070031                                                                                                                                                                                                                                         Control: 114   

  Spinal cord stimulator        Senza            NCT01609972\                                                                          Kapural et al, 2016^[@bibr30-2192568219841046]^                                                       Senza vs low-frequency stimulation at 2 years           Test: 101\     L
                                                 PMA P130022                                                                                                                                                                                                                                         Control: 97    

                                Axium            NCT01923285\                                                                          FDA SSED^[@bibr31-2192568219841046]^                                                                  Axium vs marketed control device at 3 months            Test: 76\      M
                                                 PMA P150004                                                                                                                                                                                                                                         Control: 76    

  Surgical robot                Renaissance      NCT02121249                                                                           Kim et al, 2017^[@bibr22-2192568219841046]^                                                           Robot-assisted pedicle screw accuracy vs freehand       Test: 37\      L
                                                                                                                                                                                                                                                                                                     Control: 41    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: L, low; M, medium; H, high; N/A, not applicable; FDA, US Food and Drug Administration; SSED, Summary of Safety and Effectiveness Data.

There were 19 (46%) studies designed as NI trials, 15 (37%) studies designed as NI + S trials, and 7 (17%) studies designed as superiority trials. Five of the 7 superiority trials were reported within the past 3 years ([Figure 2](#fig2-2192568219841046){ref-type="fig"}). A composite clinical success (CCS) criterion was the most common primary outcome measure and was typically defined as: an improvement in a patient reported outcome greater than a clinically relevant threshold; the absence of secondary surgical interventions or procedures; the absence of neurologic deterioration; the absence of device and/or procedure related serious adverse events; and possibly radiographic findings.^[@bibr12-2192568219841046]^

![Trends in noninferiority versus superiority designs for randomized controlled trials of spinal devices that were included in this review since the year 2000.](10.1177_2192568219841046-fig2){#fig2-2192568219841046}

Sample size calculations were often performed using the methods described by Blackwelder et al^[@bibr13-2192568219841046],[@bibr14-2192568219841046]^ with a NI margin of 10% ([Table 3](#table3-2192568219841046){ref-type="table"}). A few studies assumed other margins for power calculations, but data was also analyzed with a 10% margin at the request of the FDA.^[@bibr15-2192568219841046][@bibr16-2192568219841046][@bibr17-2192568219841046]-[@bibr18-2192568219841046]^ No study estimated the NI margin from a prior superiority study that measured the effect size compared with sham or placebo. Three of the superiority studies used Bayesian methods for sample size.^[@bibr19-2192568219841046][@bibr20-2192568219841046]-[@bibr21-2192568219841046]^ Two assumed superiority effect sizes of 9%^[@bibr22-2192568219841046]^ and 23%.^[@bibr23-2192568219841046]^ One did not describe its power analysis^[@bibr24-2192568219841046]^ and one assumed a medium effect size (Cohen's *d*=0.4) for differences in disability scores.^[@bibr25-2192568219841046]^ Three superiority studies compared with nonsurgical management,^[@bibr20-2192568219841046],[@bibr21-2192568219841046],[@bibr23-2192568219841046]^ while the rest of the studies used an active surgical control. The active surgical controls represented a standard treatment technique for the respective condition (eg, fusion as a control for disc replacements and autograft for biologics). Seven of the studies compared with devices of the same class that were already available on the market.^[@bibr18-2192568219841046],[@bibr26-2192568219841046][@bibr27-2192568219841046][@bibr28-2192568219841046][@bibr29-2192568219841046][@bibr30-2192568219841046]-[@bibr31-2192568219841046]^

###### 

Summary of Study Design Characteristics and Conclusions.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Device Type                   Device                                                                                Citation                                                                                  Hypotheses           Primary Outcome             Margin        Report Claim   Risk of Superiority Claim Bias                                                                                                               Superiority Outcomes and Considerations
  ----------------------------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- -------------------- --------------------------- ------------- -------------- -------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  Cervical disc replacement     BRYAN                                                                                 Heller et al, 2009^[@bibr33-2192568219841046]^                                            Primary: NI\         CCS                         NI: 10%       S              H                                                                                                                                            Test CCS: 83% (95% CI: 77%-87%)\
                                                                                                                                                                                                                Secondary: S                                                                                                                                                                                                               Control CCS: 73% (95% CI: 66%-79%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                           *P* = .01, one-sided FET; S claim not supported by PP analysis or sensitivity analyses of missing values

  Prestige ST                   Mummaneni et al, 2007^[@bibr15-2192568219841046]^                                     Primary: NI\                                                                              CCS                  NI: 10%                     S             M              Test CCS: 79%\                                                                                                                               
                                                                                                                      Secondary: S                                                                                                                                                            Control CCS: 68%\                                                                                                                            
                                                                                                                                                                                                                                                                                              *P* = .005, one-sided FET; Analysis population not described; FDA panel recommended limit of NI claim only                                   

  Prestige LP                   Gornet et al. 2017^[@bibr37-2192568219841046]^                                        Primary: NI\                                                                              CCS                  NI: 10%                     S             H              Test CCS: 81%\                                                                                                                               
                                                                                                                      Secondary: S                                                                                                                                                            Control CCS: 69%\                                                                                                                            
                                                                                                                                                                                                                                                                                              BPP = 0.99; As-treated analysis,\                                                                                                            
                                                                                                                                                                                                                                                                                              8%-18% of patients received different treatment; no sensitivity analysis                                                                     

  ProDisc-C                     Murrey et al, 2009^[@bibr40-2192568219841046]^                                        NI                                                                                        CCS                  NI: 10%                     CCS: NI\      H              Test mCCS: 74%\                                                                                                                              
                                                                                                                                                                                                                                                                 mCCS: S                      Control mCCS: 61%\                                                                                                                           
                                                                                                                                                                                                                                                                                              *P* = .047, one-sided FET; Original CCS confirmed NI, post hoc mCCS used for superiority test; analysis population not described             

  Kineflex C                    Coric et al. 2011^[@bibr42-2192568219841046]^                                         NI                                                                                        CCS                  NI: 10%                     S             H              Test CCS: 85%\                                                                                                                               
                                                                                                                                                                                                                                                                                              Control CCS: 71%\                                                                                                                            
                                                                                                                                                                                                                                                                                              *P* = .05, 2-sided FET; Superiority testing not prespecified; analyzed population not described                                              

  Mobi-C                        Hisey et al, 2014^[@bibr51-2192568219841046]^                                         Primary: NI\                                                                              CCS                  NI: 10%                     NI            N/A            N/A                                                                                                                                          
                                                                                                                      Secondary: S                                                                                                                                                                                                                                                                                                         

                                Davis et al, 2013a^[@bibr35-2192568219841046]^                                        Primary: NI\                                                                              CCS                  NI: 10%                     S             H              Test CCS: 70%\                                                                                                                               
                                                                                                                      Secondary: S                                                                                                                                                            Control CCS: 37%\                                                                                                                            
                                                                                                                                                                                                                                                                                              *P* \< .0001, Farrington-Manning test; Analysis of as-treated population; Sensitivity analyses only described to support NI                  

  Secure-C                      Vaccaro et al, 2013^[@bibr16-2192568219841046]^                                       Primary: NI\                                                                              CCS                  NI: 10%                     S             L              Test CCS: 84%\                                                                                                                               
                                                                                                                      Secondary: S                                                                                                                                                            Control CCS: 73%\                                                                                                                            
                                                                                                                                                                                                                                                                                              BCI: 0.6%-20%, BPP = 0.98; Sensitivity analysis not performed for S claim                                                                    

  PCM                           Phillips et al, 2013^[@bibr41-2192568219841046]^                                      NI                                                                                        CCS                  NI: 12.5%                   S             H              Test CCS: 75% (95% CI: 69%-81%)\                                                                                                             
                                                                                                                                                                                                                                                                                              Control CCS: 65% (95% CI: 57%-73%)\                                                                                                          
                                                                                                                                                                                                                                                                                              *P* = .02, one-sided *Z*-test; S analysis not defined a priori, no ITT analysis                                                              

  Lumbar disc replacement       Charite                                                                               Blumenthal et al, 2005^[@bibr52-2192568219841046]^                                        NI                   CCS                         NI: 15%       NI             N/A                                                                                                                                          N/A

  ProDisc-L                     Zigler et al, 2007^[@bibr43-2192568219841046]^                                        NI                                                                                        CCS                  NI: 12.5%                   S             H              Test CCS: 53%\                                                                                                                               
                                                                                                                                                                                                                                                                                              Control CCS: 41%\                                                                                                                            
                                                                                                                                                                                                                                                                                              *P* = .044, Stat method not specified; S analysis not defined a priori, ITT population not analyzed, 50 nonrandomized patients included      

                                Delamarter et al, 2011^[@bibr53-2192568219841046]^                                    NI                                                                                        CCS                  NI: 12.5%                   NI            N/A            N/A                                                                                                                                          

  MAVERICK                      Gornet et al, 2011^[@bibr17-2192568219841046]^                                        Primary: NI\                                                                              CCS                  NI: 10%                     S             L              Test CCS: 74%\                                                                                                                               
                                                                                                                      Secondary: S                                                                                                                                                            Control CCS: 55%\                                                                                                                            
                                                                                                                                                                                                                                                                                              *P* \< .001, one-sided FET                                                                                                                   

  Kineflex                      Pettine et al, 2011^[@bibr26-2192568219841046]^                                       NI                                                                                        ODI and VAS scores   NI: 10pt ODI and 18pt VAS   NI            N/A            N/A                                                                                                                                          

                                activL                                                                                Garcia et al, 2015^[@bibr18-2192568219841046]^                                            Primary: NI\         CCS                         NI: 10%       S              L                                                                                                                                            Treatment difference ∼ 14%\
                                                                                                                                                                                                                Secondary: S                                                                                                                                                                                                               *P* = .02, O'Brien-Fleming sequential spending function

  Biologic: Fusion              OP-1 Putty                                                                            Vaccaro et al, 2008^[@bibr54-2192568219841046]^                                           NI                   CCS                         NR            NI             N/A                                                                                                                                          N/A

                                Delawi et al, 2016^[@bibr55-2192568219841046]^                                        NI                                                                                        CCS                  NI: 15%                     Inferior      N/A            N/A                                                                                                                                          

  Novosis (rhBMP-2)             Cho et al, 2017^[@bibr56-2192568219841046]^                                           NI                                                                                        Fusion rate          NI: 10%                     NI            N/A            N/A                                                                                                                                          

  Bonion                        Yi et al, 2015^[@bibr57-2192568219841046]^                                            NI                                                                                        Fusion rate          NI: 15%                     NI            N/A            N/A                                                                                                                                          

  i-Factor                      Arnold et al, 2016^[@bibr58-2192568219841046]^                                        Efficacy: NI\                                                                             CCS                  NI:\                        S             H              Test CCS: 69%\                                                                                                                               
                                                                                                                      Safety: S                                                                                                      10-15%                                                   Control CCS: 57%\                                                                                                                            
                                                                                                                                                                                                                                                                                              *P* = .038, Wald asymptotic approach; Failed safety superiority endpoint; S claim based on CCS that was not predefined in statistical plan   

  INFUSE with LT-cage           Burkus et al, 2002^[@bibr59-2192568219841046]^ and 2003^[@bibr60-2192568219841046]^   Primary: NI\                                                                              Fusion rate          NR                          NI            N/A            N/A                                                                                                                                          
                                                                                                                      Secondary: S                                                                                                                                                                                                                                                                                                         

  AMPLIFY (rhBMP-2)             FDA Executive Summary^[@bibr61-2192568219841046]^                                     Primary: NI\                                                                              CCS                  NI: 10%                     NI            N/A            N/A                                                                                                                                          
                                                                                                                      Secondary: S                                                                                                                                                                                                                                                                                                         

  Adhesion barrier              Oxiplex/SP                                                                            FDA Executive Summary^[@bibr24-2192568219841046]^                                         S                    LSOQ                        S: 0          Not S          N/A                                                                                                                                          N/A

  Vertobroplasty                Cortoss                                                                               Bae et al, 2012^[@bibr63-2192568219841046]^                                               NI                   VAS and ODI                 \\NI: 12.5%   NI             N/A                                                                                                                                          N/A

                                Kiva                                                                                  Tutton et al, 2015^[@bibr64-2192568219841046]^                                            Primary: NI\         CCS                         NI: 12.5%     NI             N/A                                                                                                                                          N/A
                                                                                                                                                                                                                Secondary: S                                                                                                                                                                                                               

  Dural sealant                 Adherus                                                                               Strong et al, 2017^[@bibr27-2192568219841046]^                                            NI                   CCS                         NI: 10%       NI             N/A                                                                                                                                          N/A

  Interlaminar/Spinous spacer   Superion                                                                              Patel et al, 2015^[@bibr28-2192568219841046]^                                             NI                   CCS                         NI: 10%       NI             N/A                                                                                                                                          N/A

  Coflex                        Davis et al, 2013b^[@bibr46-2192568219841046]^                                        Primary: NI\                                                                              CCS                  NI: 10%                     NI            N/A            N/A                                                                                                                                          
                                                                                                                      Secondary: S                                                                                                                                                                                                                                                                                                         

                                Schmidt et al, 2018^[@bibr25-2192568219841046]^                                       S                                                                                         CCS                  S: 0                        S             L              Test CCS: 58%\                                                                                                                               
                                                                                                                                                                                                                                                                                              Control CCS: 42%\                                                                                                                            
                                                                                                                                                                                                                                                                                              95% CI of difference: 3%-30%\                                                                                                                
                                                                                                                                                                                                                                                                                              *P* = .017; No sensitivity analysis                                                                                                          

  Aperius                       Meyer et al, 2018^[@bibr47-2192568219841046]^                                         NI                                                                                        PF of ZCQ            NI: 10%                     NI            N/A            N/A                                                                                                                                          

  X-Stop                        Strömqvist et al, 2013^[@bibr48-2192568219841046]^                                    NI                                                                                        ZCQ                  NR                          NI            N/A            N/A                                                                                                                                          

                                FDA SSED^[@bibr44-2192568219841046]^ and memo^[@bibr23-2192568219841046]^             S                                                                                         CCS                  S: 0                        S             L              Test CCS: 46%\                                                                                                                               
                                                                                                                                                                                                                                                                                              Control CCS: 5%\                                                                                                                             
                                                                                                                                                                                                                                                                                              *P* \< .001, 2-sided FET\                                                                                                                    
                                                                                                                                                                                                                                                                                              Nonoperative care as control                                                                                                                 

                                DIAM                                                                                  FDA Executive Summary^[@bibr21-2192568219841046]^                                         S                    CCS                         S: 0          S              H                                                                                                                                            Test CCS: 64%\
                                                                                                                                                                                                                                                                                                                                                                                                                                           Control CCS: 15%\
                                                                                                                                                                                                                                                                                                                                                                                                                                           BPP = 1.0\
                                                                                                                                                                                                                                                                                                                                                                                                                                           Nonoperative care as control\
                                                                                                                                                                                                                                                                                                                                                                                                                                           High rate (\>40%) of crossover in primary analysis dataset; No sensitivity analysis discussed; Not approved by FDA

  Annular closure device        Barricaid                                                                             Thomé et al, 2018^[@bibr19-2192568219841046]^                                             S                    CCS & recurrence            S: 0          S              L                                                                                                                                            Test mCCS: 76%\
                                                                                                                                                                                                                                                                                                                                                                                                                                           Control mCCS: 66%\
                                                                                                                                                                                                                                                                                                                                                                                                                                           95% CI of difference: 2%-18%, *P* \< .02\
                                                                                                                                                                                                                                                                                                                                                                                                                                           Test recurrence: 50%\
                                                                                                                                                                                                                                                                                                                                                                                                                                           Control recurrence: 70%\
                                                                                                                                                                                                                                                                                                                                                                                                                                           95% CI of difference: −12% to −28%, *P* \< .001

  Sacroiliac joint fusion       iFuse                                                                                 Whang et al, 2015^[@bibr20-2192568219841046]^                                             S                    CCS                         S: 0          S              M                                                                                                                                            Test CCS: 81% (72%-88%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                           Control CCS: 24% (13%-39%)\
                                                                                                                                                                                                                                                                                                                                                                                                                                           BPP \> 0.999; Analysis population and sensitivity analysis not reported;\
                                                                                                                                                                                                                                                                                                                                                                                                                                           Nonoperative care as control

  Interbody fusion spacer       Novomax                                                                               Lee et al, 2016^[@bibr29-2192568219841046]^                                               NI                   Fusion rate                 NI: 15%       NI             N/A                                                                                                                                          N/A

                                BAK/C                                                                                 Hacker et al, 2000^[@bibr65-2192568219841046]^ and FDA SSED^[@bibr66-2192568219841046]^   NI                   CCS                         NR            NI             N/A                                                                                                                                          N/A

  Dynamic stabilization         Dynesys                                                                               FDA Executive Summary^[@bibr67-2192568219841046]^                                         NI                   CCS                         NI: 10%       NI             N/A                                                                                                                                          N/A

  Spinal cord stimulator        Senza                                                                                 Kapural et al, 2016^[@bibr30-2192568219841046]^                                           Primary: NI\         ≥50% pain reduction         NI: 10%       S              L                                                                                                                                            Test back pain response: 77%\
                                                                                                                                                                                                                Secondary: S                                                                                                                                                                                                               Control back pain response: 49%\
                                                                                                                                                                                                                                                                                                                                                                                                                                           95% CI of difference: 10%-42%, *P* \< .001\
                                                                                                                                                                                                                                                                                                                                                                                                                                           Test leg pain response: 73%\
                                                                                                                                                                                                                                                                                                                                                                                                                                           Control leg pain response: 49%\
                                                                                                                                                                                                                                                                                                                                                                                                                                           95% CI of difference: 6%-39%, *P* = .003

  Axium                         PMA P150004^[@bibr31-2192568219841046]^                                               Primary: NI\                                                                              CCS                  NI: 10%                     S             L              Test CCS: 81% (95% CI: 70%-90%)\                                                                                                             
                                                                                                                      Secondary: S                                                                                                                                                            Control CCS: 56% (95% CI: 43%-68%)\                                                                                                          
                                                                                                                                                                                                                                                                                              *P* = .0004                                                                                                                                  

  Surgical robot                Renaissance                                                                           Kim et al, 2017^[@bibr22-2192568219841046]^                                               S                    Screw accuracy              S: 9%         Not S          N/A                                                                                                                                          N/A
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: NI, noninferiority; S, superiority; NR, not reported; N/A, not applicable; H, high; M, medium; L, low; PP, per-protocol; ITT, intention to treat; FDA, US Food and Drug Administration; BPP, Bayesian posterior probability; BCI, Bayesian credible interval; FET, Fisher's exact test; CB, confidence bound; CCS, composite clinical success (reports often referred to this as "overall success"); mCCS, modified CCS; PF of ZCQ, physical function component of Zurich Claudication Questionnaire.

The overall risk of study bias was low in 22 of the 41 studies (54%), medium in 18 (44%), and high in 1 (2%) of the studies ([Table 2](#table2-2192568219841046){ref-type="table"}; Supplementary Table S1). Medium risk ratings were attributable to potential attrition bias, an unclear blinding of outcome assessors, or potential limitations in randomization. The study with a high risk of bias suffered from a high rate of crossover subjects in the primary analysis dataset, a lack of sensitivity analyses, and uncertainty of concurrent interventions that could confound outcomes. The use of independent assessors, such as radiologists who were blinded to other outcomes, was considered an appropriate substitute for investigator blinding. Financial disclosure statements were only provided in 23 (56%) of the reports.

Evaluation of Superiority Claims {#section8-2192568219841046}
--------------------------------

Among the 19 NI studies, 4 (21%) made post hoc superiority claims. Ten of the 15 (67%) NI + S studies and 5 of the 7 (71%) superiority trials satisfied their a priori superiority hypothesis ([Table 3](#table3-2192568219841046){ref-type="table"}). All 19 superiority conclusions were based on statistical analyses with a superiority margin equal to zero. Although none of the studies discussed the superiority margin, the difference in proportions of treatment success (CCS) exceeded a +10% margin in 16 of the 19 studies ([Table 3](#table3-2192568219841046){ref-type="table"}). However, the lower bound of the 95% confidence interval did not exceed +10% in most of the studies reporting that information.

The superiority claims in 4 of the 10 NI + S studies were found to be at a high risk of bias and 1 was at a medium risk of bias ([Table 3](#table3-2192568219841046){ref-type="table"}; Supplementary Table S2). The NI + S study with a medium risk of bias for the superiority claim did not describe the analysis population and the FDA panel recommended only allowing NI claims.^[@bibr15-2192568219841046],[@bibr32-2192568219841046]^ In 1 NI + S study at a high risk of bias, the superiority claim was not robust to the sensitivity analyses of imputed values or the per-protocol analysis.^[@bibr33-2192568219841046],[@bibr34-2192568219841046]^ Two other NI+S studies at high risk of bias performed the superiority analysis on the as-treated population rather than the ITT population and did not describe any sensitivity analyses for the population or missing value imputations.^[@bibr35-2192568219841046][@bibr36-2192568219841046][@bibr37-2192568219841046]-[@bibr38-2192568219841046]^ This is particularly important when up to 18% of patients did not receive the assigned treatment, which could compromise the efficacy of randomization.^[@bibr37-2192568219841046]^ The fourth NI + S study at high risk of bias only reported the safety analysis to be a predefined superiority analysis, which failed to meet statistical superiority; yet, overall success rates were claimed to be superior.^[@bibr39-2192568219841046]^

All 4 superiority claims from NI studies were rated to be at a high risk of bias due to the apparent post hoc specification of the superiority hypothesis and lack of multiplicity adjustment.^[@bibr40-2192568219841046][@bibr41-2192568219841046][@bibr42-2192568219841046]-[@bibr43-2192568219841046]^ Furthermore, the analysis population was either not described^[@bibr40-2192568219841046],[@bibr42-2192568219841046]^ or the per-protocol population was used^[@bibr41-2192568219841046],[@bibr43-2192568219841046]^ in each of these studies. One NI study claimed superiority based solely on a post hoc modified CCS outcome since only NI could be claimed with the original primary endpoint.^[@bibr40-2192568219841046]^

Three of the 5 superiority trials were rated as a low risk of bias for the superiority claim,^[@bibr19-2192568219841046],[@bibr23-2192568219841046],[@bibr25-2192568219841046],[@bibr44-2192568219841046]^ 1 was rated with a medium risk of bias due to the lack of reporting on the analysis population or sensitivity analyses,^[@bibr20-2192568219841046]^ and 1 was at a high risk of bias due to a high rate of crossover in the primary analysis dataset, no sensitivity analyses, and potentially confounding concurrent interventions.^[@bibr21-2192568219841046]^ The study at high risk of bias did not lead to FDA approval of the investigational device. Among these 5 superiority trials, only 2 described sensitivity analyses (the conclusions were robust to the alternate analyses).^[@bibr19-2192568219841046],[@bibr23-2192568219841046]^ Although it was not considered in the risk of bias evaluation, 12 of the 19 (63%) studies claiming superiority reported the associated confidence intervals, which are useful for understanding the effect size. These 12 studies were comprised of 1 of the 4 NI studies, 7 of the 10 NI + S studies, and 4 of the 5 superiority studies.

Discussion {#section9-2192568219841046}
==========

The majority of RCTs for spinal device trials are designed primarily as NI trials based on effect size, secondary benefits, or ethical considerations; however, sponsors frequently attempt to establish post hoc superiority claims. The present study demonstrates that post hoc superiority claims derived from NI trials often suffer from a high to medium risk of bias due to analyzing the per-protocol or as-treated populations without sensitivity analysis, the claims not being robust during sensitivity analysis, or the claim being based on post hoc modified endpoints. This is important, since sponsors are under pressure from physicians, payers, and health care systems to demonstrate improvements in safety, efficacy, and cost-effectiveness. By claiming superiority in some aspects of safety and effectiveness, the sponsor can argue an improved value proposition. The current study suggests that such post hoc claims may be valid in some instances but should be scrutinized closely by the intended audiences.

The strengths of the present study include the use of multiple databases, the inclusion of important governmental databases in addition to indices of journal articles, a rigorous query methodology, and the use of multiple reviewers to eliminate false positives and combine duplicates from the query results. However, there are several shortcomings to the results. No set of databases or queries can assure complete capture of relevant results. Also, many RCTs have multiple published reports at multiple follow-up timepoints. We focused on the timepoint for the trial's primary endpoint; however, it is possible that additional superiority claims were made at later timepoints. Published protocols that provided adequate details of the a priori study plans were usually unavailable. A published protocol was only identified for 1 study.^[@bibr19-2192568219841046],[@bibr45-2192568219841046]^ Another limitation was that important details were sometimes not reported, which resulted in an "Unclear" rating for the bias assessments. Similarly, the disclosure of potential conflicts-of-interest was not consistent and could not be meaningfully collected and analyzed. While regulatory bodies and payers may receive additional, nonpublic details of the trials from the sponsor, other researchers must rely on publicly available data. Finally, only superiority claims related to primary outcomes at the primary endpoint were evaluated in this review; however, analyses of secondary outcomes specified a priori can be important for determining the utility of a new device, particularly for NI trials.

Only 17% of the reviewed RCTs of spinal devices since 2000 were designed as superiority trials. Major categories of NI trials included disc replacements (15 studies), biologics for fusion (7 studies), and interspinous/interlaminar spacers (7 studies). Most disc replacement studies compared with fusion, offering the secondary advantage of retaining range of motion. While some of these studies included radiographic measures of motion or fusion, they still used a NI design for the primary endpoint. Biologics studies had the secondary advantage of avoiding donor site morbidity compared with autologous iliac bone grafts, but this was not articulated as a superiority hypothesis and was only indirectly captured in patient reported outcomes described in the NI hypothesis. Interlaminar and interspinous process spacers are promoted as less invasive surgery, but only 1 trial compared an interlaminar device directly to fusion in order to justify the implication that reduced operating room time and blood loss resulted in a net benefit.^[@bibr46-2192568219841046]^ Other reports comparing interspinous process spacers to decompressive surgery alone referred to improving patient satisfaction, complication rates, and reducing subsequent surgical interventions for the potential advantages of the new devices.^[@bibr47-2192568219841046],[@bibr48-2192568219841046]^ Such comparisons would be most appropriate as a superiority trial with adverse events included in the CCS, as exemplified by Schmidt et al^[@bibr25-2192568219841046]^ for an interspinous process spacer versus decompression and analogously by Thomé et al^[@bibr19-2192568219841046]^ for an annular closure device compared with discectomy alone. Updates to the Consolidated Standards of Reporting Trials (CONSORT) statement were proposed in 2006^[@bibr49-2192568219841046]^ and incorporated in 2012,^[@bibr50-2192568219841046]^ which suggest that studies should report the rationale for adopting a NI design and the associated NI margin. Most NI or NI + S studies published after these updates did not specifically discuss rationale for NI vs. superiority designs. Furthermore, only 4 reports provided any rationale for the NI margin, referring to requirements by the FDA.

Using well-rounded CCS measures as the primary endpoint may reduce the options for secondary benefits of the device beyond possible economic advantages. Among the reviewed RCTs on disc replacement, the primary endpoint CCS rates in the control group (fusion) ranged from 37% to 73%^[@bibr15-2192568219841046],[@bibr16-2192568219841046],[@bibr33-2192568219841046],[@bibr35-2192568219841046],[@bibr37-2192568219841046],[@bibr40-2192568219841046][@bibr41-2192568219841046]-[@bibr42-2192568219841046],[@bibr51-2192568219841046]^ for cervical discs and from 41% to 55%^[@bibr17-2192568219841046],[@bibr43-2192568219841046],[@bibr52-2192568219841046],[@bibr53-2192568219841046]^ for lumbar discs, suggesting that a ceiling effect should not be a concern in those studies. Yet each disc replacement was evaluated with NI as the primary hypothesis and superiority as the secondary hypothesis. By focusing on appropriate endpoints, at-risk populations, and CCS criteria that demand well-rounded device success, the ceiling effect can be diminished and areas for improvement can be elucidated.

This review observed four superiority claims made through post hoc analyses of NI trials. These superiority claims were inherently at a high risk of bias due to post hoc hypothesis specification in a confirmatory trial.^[@bibr4-2192568219841046]^ Furthermore, 50% of the superiority claims from NI+S studies were observed to be at a medium or high risk of bias due to inappropriate methodology for analysis or interpretation of the superiority hypothesis. This was usually attributable to analyzing the as-treated or per-protocol population without consideration of the ITT dataset. Relying solely on as-treated or per-protocol analyses could bias the conclusions, particularly if a significant number of patients did not receive the assigned treatment, there was missing follow-up data, or significant attrition.^[@bibr7-2192568219841046]^ Overall, such deficiencies were apparent in 64% (9/14) of the NI or NI + S studies making superiority claims, which demonstrates the challenge of ensuring high fidelity conclusions when the superiority hypothesis is secondary to the NI design.

Based on the studies reviewed herein alongside the theoretical considerations of trial design and interpretation, superiority claims derived from NI trials may have a greater likelihood of confounding by methodological mistakes, ambiguities or sources of bias compared to claims derived from superiority trials. However, RCTs with an NI + S design can indeed be rigorous and present superiority claims with high levels of confidence. A few of the reviewed NI+S studies had a low risk of bias in the superiority conclusion because of the meticulous nature of the analysis and reporting, which included sensitivity analyses of both the population dataset and missing value imputations along with confidence intervals that demonstrated substantial margins.^[@bibr17-2192568219841046],[@bibr18-2192568219841046],[@bibr30-2192568219841046],[@bibr31-2192568219841046]^ The rationale for conducting these studies as NI + S trials rather than focusing on superiority was unclear. Regulatory or commercial considerations may provide a possible explanation.

Conclusions {#section10-2192568219841046}
===========

Spine studies rarely employ superiority designs for confirmatory trials. NI studies can sometimes yield reliable superiority claims, but meticulous study conduct, analysis, reporting, and interpretation is paramount. Considering the singular goal of superiority trials and the standard methodology of such designs, greater confidence may be derived more readily from the resulting superiority claims. Investigators and sponsors are encouraged to consider superiority trial designs when evaluating novel technologies against a standard of care when feasible. Readers are encouraged to carefully evaluate the risk of bias behind each superiority claim by examining the methodology of the study and associated analyses.
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